Statins enhance extracellular release of hepatitis C virus particles through ERK5 activation
Microbiology and Immunology · 2024
DOI: 10.1111/1348-0421.13166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2024. Verfasst von Chie Aoki-Utsubo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Graduate School of Health Sciences, Kobe University, Kobe, Japan. Hauptthemen laut MEDLINE: Hepacivirus, Lovastatin, Virus Replication, Virion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Japan Science and Technology Agency (JST), Japan International Cooperation Agency (JICA), Japan Agency for Medical Research Development.
Abstract (Originalsprache)
Statins, such as lovastatin, have been known to inhibit 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase. Statins were reported to moderately suppress hepatitis C virus (HCV) replication in cultured cells harboring HCV RNA replicons. We report here using an HCV cell culture (HCVcc) system that high concentrations of lovastatin (5–20 μg/mL) markedly enhanced the release of HCV infectious particles (virion) in the culture supernatants by up to 40 times, without enhancing HCV RNA replication, HCV protein synthesis, or HCV virion assembly in the cells. We also found that lovastatin increased the phosphorylation (activation) level of extracellular‐signal‐regulated kinase 5 (ERK5) in both the infected and uninfected cells in a dose‐dependent manner. The lovastatin‐mediated increase of HCV virion release was partially reversed by selective ERK5 inhibitors, BIX02189 and XMD8‐92, or by ERK5 knockdown using small interfering RNA (siRNA). Moreover, we demonstrated that other cholesterol‐lowering statins, but not dehydrolovastatin that is incapable of inhibiting HMG‐CoA reductase and activating ERK5, enhanced HCV virion release to the same extent as observed with lovastatin. These results collectively suggest that statins markedly enhance HCV virion release from infected cells through HMG‐CoA reductase inhibition and ERK5 activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, Graduate School of Health Sciences, Kobe University, Kobe, Japan.
- Division of Infectious Disease Control, Graduate School of Medicine, Kobe University, Kobe, Japan.
- Research Center for Chemistry, National Research and Innovation Agency (BRIN), Serpong, Indonesia.
- Department of Microbiology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
- National Institute of Infectious Diseases, Tokyo, Japan.
- Faculty of Clinical Nutrition and Dietetics, Konan Women's University, Kobe, Japan.
Förderung
- Japan Science and Technology Agency (JST)
- Japan International Cooperation Agency (JICA)
- Japan Agency for Medical Research Development
- Japan Society for the Promotion of Science
- Research Center for Chemistry, National Research and Innovation Agency (BRIN)
Zitieren
APA
Aoki-Utsubo, C., Kameoka, M., Deng, L., Hanafi, M., Dewi, B. E., Sudarmono, P., Wakita, T., & Hotta, H. (2024). Statins enhance extracellular release of hepatitis C virus particles through ERK5 activation. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.13166
Vancouver
Aoki-Utsubo C, Kameoka M, Deng L, Hanafi M, Dewi BE, Sudarmono P, et al. Statins enhance extracellular release of hepatitis C virus particles through ERK5 activation. Microbiology and Immunology. 2024. doi:10.1111/1348-0421.13166
BibTeX
@article{AokiUtsubo2024,
author = {Aoki-Utsubo, Chie and Kameoka, Masanori and Deng, Lin and Hanafi, Muhammad and Dewi, Beti Ernawati and Sudarmono, Pratiwi and Wakita, Takaji and Hotta, Hak},
title = {Statins enhance extracellular release of hepatitis C virus particles through ERK5 activation},
journal = {Microbiology and Immunology},
year = {2024},
doi = {10.1111/1348-0421.13166}
}
EUVIMED